Mineralocorticoids, hypertension, and cardiac fibrosis.
Open Access
- 1 June 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 93 (6), 2578-2583
- https://doi.org/10.1172/jci117269
Abstract
Uninephrectomized rats drinking 1% sodium chloride were given aldosterone (Aldo, 0.75 microgram/h, subcutaneous [s.c.] infusion), deoxycorticosterone (DOC, 20 mg/wk, s.c.), corticosterone (B, 2 mg/d, s.c.), or the antiglucocorticoid-antiprogestin RU486 (2 mg/d, s.c.) for 8 wk, and hemodynamic and tissue responses were compared with a non-steroid-treated control group. Aldo and DOC markedly increased systolic BP and caused considerable (40-50%) cardiac hypertrophy; B and RU486 caused neither hypertension nor cardiac hypertrophy. Measurements of ventricular cross-sectional areas showed hypertrophy due to an increase in mass of the left ventricle only. Cardiac hydroxyproline concentration was increased considerably by Aldo and DOC, to a lesser degree by RU486, and not by B. Aldo markedly elevated left ventricular interstitial collagen (2.5-fold vs control, P < 0.01 vs all groups); other steroid treatments also increased interstitial collagen over control (DOC x 1.8-, RU486 x 1.6-, B x 1.3-fold), with identical responses for right and left ventricles (r = 0.94). A different pattern of perivascular fibrosis was noted; DOC elevated perivascular collagen (2.1-fold vs control, P < 0.01 vs all other groups); RU486 raised levels 1.4-fold vs control, but neither Aldo nor B significantly affected perivascular collagen. These data are consistent with interstitial cardiac fibrosis reflecting type I (mineralocorticoid) receptor occupancy by administered Aldo or DOC, or by elevated endogenous B after type II (glucocorticoid) receptor blockade after RU486 administration; perivascular fibrosis may reflect a composite response after type I receptor agonist/type II glucocorticoid receptor antagonist occupancy.This publication has 20 references indexed in Scilit:
- Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary HyperaldosteronismJournal of Molecular and Cellular Cardiology, 1993
- ON MAKING MULTIPLE COMPARISONS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGYClinical and Experimental Pharmacology and Physiology, 1991
- Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormoneCell, 1990
- Mineralocorticoid Action: Target Tissue Specificity Is Enzyme, Not Receptor, MediatedScience, 1988
- LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTORThe Lancet, 1988
- Cloning of Human Mineralocorticoid Receptor Complementary DNA: Structural and Functional Kinship with the Glucocorticoid ReceptorScience, 1987
- Picrosirius Red Staining of Cardiac Muscle Following Phosphomolybdic Acid TreatmentStain Technology, 1987
- HIGH-AFFINITY ALDOSTERONE BINDING IN RAT LIVER?A RE-EVALUATIONClinical and Experimental Pharmacology and Physiology, 1987
- A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusionJournal of Molecular and Cellular Cardiology, 1986
- Corticosteroid metabolism in isolated rat kidney in vitroPflügers Archiv - European Journal of Physiology, 1984